#USA #New York #Gross Law Firm #ARS Pharmaceuticals #SPRY

ARS Pharmaceuticals, Inc. Class Action Update

The Gross Law Firm has recently issued an important notice directed at investors who own shares of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY). Shareholders who purchased their shares during the specified class period are encouraged to engage with the firm regarding potential lead plaintiff appointments. It's crucial for those affected by the recent negative developments surrounding the company to understand their options in this pressing matter.

Class Period Overview

From March 9, 2026, to June 24, 2026, investors were led to believe that ARS Pharmaceuticals was making significant progress in getting expanded insurance coverage for its product, neffy, through CVS Caremark. The company had consistently issued optimistic statements, which later proved to be misleading. On June 24, 2026, ARS announced that it had not achieved the intended expanded coverage by the previously guided deadline of July 1, 2026. This revelation was met with swift disappointment, leading to a sharp decline in stock values.

Market Reaction

Following the announcement, ARS Pharmaceuticals' stock plummeted over 23.9%, dropping from a closing price of $10.54 on June 24 to $8.02 on June 25. This abrupt market reaction underscores the significant impact of the news on investor confidence and the pressing need for accountability from the company.

Deadline for Participation

The final date for shareholders to register for this class action is October 5, 2026. Investors are urged not to delay in submitting their information if they purchased shares during the outlined period. Engaging with the class action can be a critical step in seeking recovery for their losses.

Steps for Shareholders

By registering as a shareholder who acquired shares of ARS during the designated timeframe, individuals will gain access to portfolio monitoring tools that will update them on the progress of the case. Participating does not incur any fees or obligations. This is an essential opportunity for shareholders to safeguard their interests and potentially recover losses incurred due to the company's alleged misconduct.

About The Gross Law Firm

The Gross Law Firm is nationally recognized for its commitment to protecting investors' rights, especially those affected by deceptive practices and fraud. Their focus is on ensuring corporations adhere to ethical business conduct. The firm is dedicated to representing investors who have sustained losses due to companies disseminating false statements and withholding critical information that artificially inflate stock prices.

Contact Information

For further inquiries or to express interest in joining this class action, shareholders can reach out directly to The Gross Law Firm at:

• - Address: 15 West 38th Street, 12th floor, New York, NY, 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

This opportunity represents an avenue for ARS Pharmaceuticals, Inc. investors to take action against potential corporate misconduct and regain some of their investments amid troubling revelations.